A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 577 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR The Nobel Prize winner helping us treat children’s cancers November 8, 2022 Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear... March 4, 2025 Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... October 14, 2025 Is CBD Safe for People With Cancer? September 22, 2020 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΣΤΟΜΑΧΟΥ Olaparib approved for 800 prostate and breast cancer patients in England Cancer Moonshot℠ Workshop Highlights Recent Research Advances A real Eureka moment for translation
